Spots Global Cancer Trial Database for psa progression
Every month we try and update this database with for psa progression cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
| Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
|---|---|---|---|---|---|---|
| Study of ILX651 in Patients With Hormone-Refractory Prostate Cancer Previously Treated With Docetaxel | NCT00082134 | Hormone-refract... | ILX651 | 19 Years - | Sanofi | |
| Docetaxel, Carboplatin, and Rucaparib Camsylate in Treating Patients With Metastatic Castration Resistant Prostate Cancer With Homologous Recombination DNA Repair Deficiency | NCT03442556 | ATM Gene Mutati... BRCA1 Gene Muta... BRCA2 Gene Muta... Castration Leve... Castration-Resi... Homologous Reco... Prostate Carcin... PSA Level Great... PSA Progression Stage IV Prosta... | Carboplatin Docetaxel Laboratory Biom... Rucaparib Camsy... Rucaparib | 18 Years - | University of Washington | |
| Stereotactic Body Radiation Therapy in Treating Patients With Localized Prostate Cancer That Have Undergone Surgery | NCT03541850 | PSA Level Great... PSA Progression Stage I Prostat... Stage II Prosta... Stage III Prost... | Antiandrogen Th... Quality-of-Life... Stereotactic Bo... | 18 Years - | Jonsson Comprehensive Cancer Center | |
| Molecular Features and Pathways in Predicting Drug Resistance in Patients With Metastatic Castration-Resistant Prostate Cancer Receiving Enzalutamide | NCT02228265 | Castration Leve... Castration-Resi... Prostate Adenoc... PSA Progression Recurrent Prost... Stage IV Prosta... | Cytology Specim... Enzalutamide Laboratory Biom... | - | OHSU Knight Cancer Institute | |
| Pembrolizumab in Treating Patients With Metastatic Castration Resistant Prostate Cancer Previously Treated With Enzalutamide | NCT02312557 | Castration-Resi... Hormone-Resista... PSA Progression Recurrent Prost... Stage IV Prosta... | Enzalutamide Laboratory Biom... Pembrolizumab | 18 Years - | OHSU Knight Cancer Institute | |
| Selinexor in Treating Patients With Abiraterone Acetate and/or Enzalutamide Refractory Metastatic Castration-Resistant Prostate Cancer | NCT02215161 | Castration Leve... Hormone-Resista... Metastatic Pros... Prostate Carcin... PSA Progression Stage IV Prosta... | Selinexor | 18 Years - | University of California, San Francisco | |
| Enzalutamide and Decitabine in Treating Patients With Metastatic Castration Resistant Prostate Cancer | NCT03709550 | Castration Leve... Castration-Resi... Metastatic Pros... Prostate Carcin... PSA Level Great... PSA Progression Stage IV Prosta... Stage IVA Prost... Stage IVB Prost... | Decitabine Enzalutamide | 18 Years - | Roswell Park Cancer Institute | |
| Efficacy Study of Switching to a Lutenizing Hormone-releasing Hormone (LHRH) Antagonist From a LHRH Agonist to Treat Progressive Castrate Resistant Prostate Cancer (CRPC) | NCT01630967 | Prostate Neopla... | Degarelix | 18 Years - | British Columbia Cancer Agency | |
| 68GA-PSMA-11 PET/CT Scan in Impacting Treatment Strategies for Patients With Prostate Cancer | NCT04050215 | Biochemically R... Metastatic Pros... Prostate Adenoc... Prostate Carcin... PSA Level Great... PSA Progression Stage IV Prosta... Stage IVA Prost... Stage IVB Prost... | Computed Tomogr... Gallium Ga 68-l... Positron Emissi... Questionnaire A... | 18 Years - | Jonsson Comprehensive Cancer Center | |
| Dendritic Cell (DC)-Based Vaccines Loaded With Allogeneic Prostate Cell Lines in Combination With Androgen Ablation in Patients With Prostate Cancer | NCT00970203 | Cancer of Prost... Cancer of the P... Neoplasms, Pros... Neoplasms, Pros... Prostate Cancer Prostate Neopla... Prostatic Cance... | androgen ablati... DC1 vaccine | 18 Years - | Roswell Park Cancer Institute | |
| ESK981 in Treating Patients With Metastatic Castrate-Resistant Prostate Cancer | NCT03456804 | Castration Leve... Castration-Resi... Metastatic Pros... PSA Progression Stage IV Prosta... | ESK981 | 18 Years - | Barbara Ann Karmanos Cancer Institute | |
| Stereotactic Body Radiation Therapy in Treating Patients With Localized Prostate Cancer That Have Undergone Surgery | NCT03541850 | PSA Level Great... PSA Progression Stage I Prostat... Stage II Prosta... Stage III Prost... | Antiandrogen Th... Quality-of-Life... Stereotactic Bo... | 18 Years - | Jonsson Comprehensive Cancer Center | |
| F18 DCFPyL PET/CT in Imaging Participants With Recurrent Prostate Cancer | NCT03501940 | Prostate Adenoc... PSA Level Great... PSA Level Great... PSA Progression Recurrent Prost... | Computed Tomogr... Fluorine F 18 D... Laboratory Biom... Positron Emissi... | 18 Years - | Stanford University | |
| Apalutamide With or Without Stereotactic Body Radiation in Treating Castration-Resistant Prostate Cancer | NCT03503344 | Castration Leve... Castration-Resi... PSA Progression Stage IV Prosta... | Apalutamide Stereotactic Bo... | 18 Years - | University of California, San Francisco | |
| Enzalutamide and Decitabine in Treating Patients With Metastatic Castration Resistant Prostate Cancer | NCT03709550 | Castration Leve... Castration-Resi... Metastatic Pros... Prostate Carcin... PSA Level Great... PSA Progression Stage IV Prosta... Stage IVA Prost... Stage IVB Prost... | Decitabine Enzalutamide | 18 Years - | Roswell Park Cancer Institute | |
| Pembro and HER2Bi-Armed Activated T Cells in Treating Patients With Metastatic Castration Resistant Prostate Cancer | NCT03406858 | Castration Leve... Castration-Resi... Prostate Carcin... PSA Progression Stage IV Prosta... | HER2Bi-Armed Ac... Laboratory Biom... Pembrolizumab | 19 Years - | Barbara Ann Karmanos Cancer Institute | |
| F18 DCFPyL PET/CT in Imaging Participants With Recurrent Prostate Cancer | NCT03501940 | Prostate Adenoc... PSA Level Great... PSA Level Great... PSA Progression Recurrent Prost... | Computed Tomogr... Fluorine F 18 D... Laboratory Biom... Positron Emissi... | 18 Years - | Stanford University | |
| Dendritic Cell (DC)-Based Vaccines Loaded With Allogeneic Prostate Cell Lines in Combination With Androgen Ablation in Patients With Prostate Cancer | NCT00970203 | Cancer of Prost... Cancer of the P... Neoplasms, Pros... Neoplasms, Pros... Prostate Cancer Prostate Neopla... Prostatic Cance... | androgen ablati... DC1 vaccine | 18 Years - | Roswell Park Cancer Institute | |
| Gallium Ga 68 DOTA-NeoBOMB1 and Gallium Ga 68 PSMA-R2 PET/MRI in Diagnosing Participants With Recurrent Prostate Cancer | NCT03698370 | Prostate Adenoc... PSA Progression Recurrent Prost... | Gallium Ga 68 D... Gallium Ga 68 P... | 18 Years - | Stanford University | |
| Pembro and HER2Bi-Armed Activated T Cells in Treating Patients With Metastatic Castration Resistant Prostate Cancer | NCT03406858 | Castration Leve... Castration-Resi... Prostate Carcin... PSA Progression Stage IV Prosta... | HER2Bi-Armed Ac... Laboratory Biom... Pembrolizumab | 19 Years - | Barbara Ann Karmanos Cancer Institute | |
| Apalutamide With or Without Stereotactic Body Radiation in Treating Castration-Resistant Prostate Cancer | NCT03503344 | Castration Leve... Castration-Resi... PSA Progression Stage IV Prosta... | Apalutamide Stereotactic Bo... | 18 Years - | University of California, San Francisco | |
| Enzalutamide With Venetoclax in Treating Patients With Metastatic Castration Resistant Prostate Cancer | NCT03751436 | Castration Leve... Castration-Resi... Metastatic Pros... Metastatic Pros... Prostate Carcin... PSA Progression Stage IV Prosta... Stage IVA Prost... Stage IVB Prost... | Enzalutamide Venetoclax | 18 Years - | Roswell Park Cancer Institute | |
| F18 DCFPyL PET/CT in Imaging Participants With Recurrent Prostate Cancer | NCT03501940 | Prostate Adenoc... PSA Level Great... PSA Level Great... PSA Progression Recurrent Prost... | Computed Tomogr... Fluorine F 18 D... Laboratory Biom... Positron Emissi... | 18 Years - | Stanford University | |
| 68GA-PSMA-11 PET/CT Scan in Impacting Treatment Strategies for Patients With Prostate Cancer | NCT04050215 | Biochemically R... Metastatic Pros... Prostate Adenoc... Prostate Carcin... PSA Level Great... PSA Progression Stage IV Prosta... Stage IVA Prost... Stage IVB Prost... | Computed Tomogr... Gallium Ga 68-l... Positron Emissi... Questionnaire A... | 18 Years - | Jonsson Comprehensive Cancer Center | |
| Enzalutamide and Decitabine in Treating Patients With Metastatic Castration Resistant Prostate Cancer | NCT03709550 | Castration Leve... Castration-Resi... Metastatic Pros... Prostate Carcin... PSA Level Great... PSA Progression Stage IV Prosta... Stage IVA Prost... Stage IVB Prost... | Decitabine Enzalutamide | 18 Years - | Roswell Park Cancer Institute | |
| Gallium Ga 68 DOTA-NeoBOMB1 and Gallium Ga 68 PSMA-R2 PET/MRI in Diagnosing Participants With Recurrent Prostate Cancer | NCT03698370 | Prostate Adenoc... PSA Progression Recurrent Prost... | Gallium Ga 68 D... Gallium Ga 68 P... | 18 Years - | Stanford University | |
| Enzalutamide With Venetoclax in Treating Patients With Metastatic Castration Resistant Prostate Cancer | NCT03751436 | Castration Leve... Castration-Resi... Metastatic Pros... Metastatic Pros... Prostate Carcin... PSA Progression Stage IV Prosta... Stage IVA Prost... Stage IVB Prost... | Enzalutamide Venetoclax | 18 Years - | Roswell Park Cancer Institute | |
| Pembrolizumab in Treating Patients With Metastatic Castration Resistant Prostate Cancer Previously Treated With Enzalutamide | NCT02312557 | Castration-Resi... Hormone-Resista... PSA Progression Recurrent Prost... Stage IV Prosta... | Enzalutamide Laboratory Biom... Pembrolizumab | 18 Years - | OHSU Knight Cancer Institute | |
| ESK981 in Treating Patients With Metastatic Castrate-Resistant Prostate Cancer | NCT03456804 | Castration Leve... Castration-Resi... Metastatic Pros... PSA Progression Stage IV Prosta... | ESK981 | 18 Years - | Barbara Ann Karmanos Cancer Institute | |
| ESK981 in Treating Patients With Metastatic Castrate-Resistant Prostate Cancer | NCT03456804 | Castration Leve... Castration-Resi... Metastatic Pros... PSA Progression Stage IV Prosta... | ESK981 | 18 Years - | Barbara Ann Karmanos Cancer Institute | |
| ESK981 in Treating Patients With Metastatic Castrate-Resistant Prostate Cancer | NCT03456804 | Castration Leve... Castration-Resi... Metastatic Pros... PSA Progression Stage IV Prosta... | ESK981 | 18 Years - | Barbara Ann Karmanos Cancer Institute |
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
